Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-IgG is a radiopharmaceutical consisting of nonspecific human immunoglobulin G (IgG) labeled with the radioisotope Indium-111. It is primarily utilized as a diagnostic imaging agent in nuclear medicine for the localization of focal inflammation and infection, leveraging the natural accumulation of IgG at sites of immune activity. In preclinical oncology research, 111In-IgG serves as a critical negative control for immuno-PET or SPECT studies; by comparing its biodistribution to that of a target-specific antibody, researchers can differentiate between antigen-mediated uptake and nonspecific accumulation caused by the enhanced permeability and retention (EPR) effect or blood pool activity. The tracer typically exhibits a long circulatory half-life, reflecting the pharmacokinetics of native IgG.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indium In 111 IgG.